Skip to main content

Advertisement

SpringerLink
Log in

Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

As a main effector in the renin-angiotensin system, the angiotensin II plays a critical role in cell proliferation and angiogenesis. The change between angiotensin II and its precursor is conducted by the angiotensin-converting enzyme. The association between angiotensin-converting enzyme insertion/deletion polymorphism and the activity of angiotensin-converting enzyme was testified. Furthermore, previous researches proved the association between angiotensin-converting enzyme activity and the risk of prostate cancer. Therefore, we conducted a case–control study in the Han population of China to elaborate the relation between the angiotensin-converting enzyme insertion/deletion polymorphism and prostate cancer. DNA was extracted from blood samples collected from 189 pathologically diagnosed prostate cancer patients and 290 cancer-free subjects. The angiotensin-converting enzyme insertion/deletion genotype was determined by polymerase chain reaction analysis. Stratified analyses on age (<71 or ≥71), cancer stage (localized or advanced), Gleason score (<7 or ≥7) and PSA level (<20 ng/ml or ≥20 ng/ml) were performed. We found the II genotype (OR = 0.304 95%CI (0.180,0.515), P < 0.001) and I allele (OR = 0.547 95%CI(0.421,0.711), P < 0.001) were associated with a decreased risk of prostate cancer compared with the DD genotype and D allele. The DD genotype was related to patients with aggressive stage of prostate cancer (OR = 2.214 95%CI(1.169, 4.194), P = 0.014) and patients diagnosed of prostate cancer at a relatively early age (OR = 0.513 95%CI(0.272, 0.965), P = 0.037). The results of our experiment supported the hypothesis that the angiotensin-converting enzyme insertion/deletion polymorphism, a potential risk factor in carcinogenesis, played an important role in the Han population of China.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70–98. doi:10.3322/caac.20066.

    Article  PubMed  Google Scholar 

  3. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int. 2002;90(2):162–73. doi:10.1046/j.1464-410X.2002.2822.x.

    Article  PubMed  CAS  Google Scholar 

  4. Ostrander EA, Stanford JL. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet. 2000;67(6):1367–75. doi:10.1086/316916.

    Article  PubMed  CAS  Google Scholar 

  5. Gu F. Changing constituents of genitourinary cancer in recent 50 years in Beijing. Chin Med J (Engl). 2003;116(9):1391–3.

    Google Scholar 

  6. Lindstrom S, Schumacher F, Siddiq A, Travis RC, Campa D, Berndt SI, et al. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers–results from BPC3. PLoS One. 2011;6(2):e17142. doi:10.1371/journal.pone.0017142.

    Article  PubMed  CAS  Google Scholar 

  7. Belpomme D, Irigaray P, Ossondo M, Vacque D, Martin M. Prostate cancer as an environmental disease: an ecological study in the French Caribbean islands, Martinique and Guadeloupe. Int J Oncol. 2009;34(4):1037–44.

    Article  PubMed  CAS  Google Scholar 

  8. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human prostate cancer risk factors. Cancer. 2004;101(10 Suppl):2371–490. doi:10.1002/cncr.20408.

    Article  PubMed  CAS  Google Scholar 

  9. Spitz MR, Strom SS, Yamamura Y, Troncoso P, Babaian RJ, Scardino PT, et al. Epidemiologic determinants of clinically relevant prostate cancer. Int J Cancer. 2000;89(3):259–64. doi:10.1002/1097-0215(20000520)89:3<259::AID-IJC8>3.0.CO;2-F.

    Article  PubMed  CAS  Google Scholar 

  10. Rizos C, Papassava M, Golias C, Charalabopoulos K. Alcohol consumption and prostate cancer: a mini review. Exp Oncol. 2010;32(2):66–70.

    PubMed  CAS  Google Scholar 

  11. Gard PR. Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review. Int J Mol Epidemiol Genet. 2010;1(2):145–57.

    PubMed  CAS  Google Scholar 

  12. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352(9123):179–84. doi:10.1016/S0140-6736(98)03228-0.

    Article  PubMed  CAS  Google Scholar 

  13. Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution, signalling and function. Clin Sci (Lond). 2001;100(5):481–92.

    Article  CAS  Google Scholar 

  14. Baudin B. Angiotensin II receptor polymorphisms in hypertension Pharmacogenomic considerations. Pharmacogenomics. 2002;3(1):65–73. doi:10.1517/14622416.3.1.65.

    Article  PubMed  CAS  Google Scholar 

  15. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10(11):745–59. doi:10.1038/nrc2945.

    Article  PubMed  CAS  Google Scholar 

  16. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267(16):10931–4.

    PubMed  CAS  Google Scholar 

  17. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3(2):65–71.

    PubMed  CAS  Google Scholar 

  18. Uemura H, Hasumi H, Ishiguro H, Teranishi J, Miyoshi Y, Kubota Y. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate. 2006;66(8):822–30. doi:10.1002/pros.20407.

    Article  PubMed  CAS  Google Scholar 

  19. Xi B, Zeng T, Liu L, Liang Y, Liu W, Hu Y. et al. Association between polymorphisms of the renin-angiotensin system genes and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2011. doi:10.1007/s10549-011-1602-3.

  20. Yaren A, Oztop I, Turgut S, Turgut G, Degirmencioglu S, Demirpence M. Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Exp Biol Med (Maywood). 2008;233(1):32–7. doi:10.3181/0705-RM-141.

    Article  CAS  Google Scholar 

  21. Loh M, Koh KX, Yeo BH, Song CM, Chia KS, Zhu F, et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer. 2009;45(14):2562–8. doi:10.1016/j.ejca.2009.03.017.

    Article  PubMed  CAS  Google Scholar 

  22. Sierra Diaz E, Sanchez Corona J, Rosales Gomez RC, Gutierrez Rubio SA, Vazquez Camacho JG, Solano Moreno H, et al. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer. J Renin Angiotensin Aldosterone Syst. 2009;10(4):241–6. doi:10.1177/1470320309352800.

    Article  PubMed  Google Scholar 

  23. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA. 1988;85(24):9386–90.

    Article  PubMed  CAS  Google Scholar 

  24. Hubert C, Houot AM, Corvol P, Soubrier F. Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol Chem. 1991;266(23):15377–83.

    PubMed  CAS  Google Scholar 

  25. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res. 1992;20(6):1433.

    Article  PubMed  CAS  Google Scholar 

  26. Suehiro T, Morita T, Inoue M, Kumon Y, Ikeda Y, Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet. 2004;115(2):91–6. doi:10.1007/s00439-004-1136-4.

    Article  PubMed  CAS  Google Scholar 

  27. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86(4):1343–6. doi:10.1172/JCI114844.

    Article  PubMed  CAS  Google Scholar 

  28. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51(1):197–205.

    PubMed  CAS  Google Scholar 

  29. Small W Jr, Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF. Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat. 1997;44(3):217–24.

    Article  PubMed  CAS  Google Scholar 

  30. Reddy MK, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med. 1995;210(3):221–6.

    PubMed  CAS  Google Scholar 

  31. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer. 1998;77(6):880–3.

    Article  PubMed  CAS  Google Scholar 

  32. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996;98(3):671–9. doi:10.1172/JCI118838.

    Article  PubMed  CAS  Google Scholar 

  33. Yigit B, Bozkurt N, Narter F, Yilmaz H, Yucebas E, Isbir T. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastasis. Anticancer Res. 2007;27(2):933–6.

    PubMed  CAS  Google Scholar 

  34. Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, et al. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J Pathol. 2004;202(3):330–5. doi:10.1002/path.1529.

    Article  PubMed  CAS  Google Scholar 

  35. van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam study. Cancer. 2008;112(4):748–57. doi:10.1002/cncr.23215.

    Article  PubMed  Google Scholar 

  36. Haiman CA, Henderson SO, Bretsky P, Kolonel LN, Henderson BE. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res. 2003;63(20):6984–7.

    PubMed  CAS  Google Scholar 

  37. Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res. 2003;63(3):573–8.

    PubMed  CAS  Google Scholar 

  38. Vigano A, Trutschnigg B, Kilgour RD, Hamel N, Hornby L, Lucar E, et al. Relationship between angiotensin-converting enzyme gene polymorphism and body composition, functional performance, and blood biomarkers in advanced cancer patients. Clin Cancer Res. 2009;15(7):2442–7. doi:10.1158/1078-0432.CCR-08-1720.

    Article  PubMed  CAS  Google Scholar 

  39. Rocken C, Lendeckel U, Dierkes J, Westphal S, Carl-McGrath S, Peters B, et al. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res. 2005;11(7):2526–30. doi:10.1158/1078-0432.CCR-04-1922.

    Article  PubMed  Google Scholar 

  40. Ebert MP, Lendeckel U, Westphal S, Dierkes J, Glas J, Folwaczny C, et al. The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2987–9. doi:10.1158/1055-9965.EPI-05-0411.

    Article  PubMed  CAS  Google Scholar 

  41. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58–64.

    PubMed  CAS  Google Scholar 

  42. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl. 1993;3(2):120–1.

    PubMed  CAS  Google Scholar 

  43. Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn. 2004;4(4):513–26. doi:10.1586/14737159.4.4.513.

    Article  PubMed  CAS  Google Scholar 

  44. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst. 2006;98(8):529–34. doi:10.1093/jnci/djj131.

    Article  PubMed  Google Scholar 

  45. Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, et al. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1871–8. doi:10.1158/1055-9965.EPI-10-0216.

    Article  PubMed  CAS  Google Scholar 

  46. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002;62(12):3369–72.

    PubMed  CAS  Google Scholar 

  47. Bai Y, Yu Y, Yu B, Ge J, Ji J, Lu H, et al. Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet. 2009;10:125. doi:10.1186/1471-2350-10-125.

    Article  PubMed  Google Scholar 

  48. Li H, Qi Y, Li C, Braseth LN, Gao Y, Shabashvili AE, et al. Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther. 2009;8(12):3255–65. doi:10.1158/1535-7163.MCT-09-0237.

    Article  PubMed  CAS  Google Scholar 

  49. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate. 2007;67(9):924–32. doi:10.1002/pros.20571.

    Article  PubMed  CAS  Google Scholar 

  50. Hoshino K, Ishiguro H, Teranishi J, Yoshida S, Umemura S, Kubota Y, et al. Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate. 2011;71(9):964–75. doi:10.1002/pros.21312.

    Article  PubMed  CAS  Google Scholar 

  51. Attoub S, Gaben AM, Al-Salam S, Al Sultan MA, John A, Nicholls MG, et al. Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci. 2008;1138:65–72. doi:10.1196/annals.1414.011.

    Article  PubMed  CAS  Google Scholar 

  52. Hamdi HK, Castellon R. A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. Biochem Biophys Res Commun. 2004;318(1):187–91. doi:10.1016/j.bbrc.2004.04.004.

    Article  PubMed  CAS  Google Scholar 

  53. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H, et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol. 2002;20(6):1227–31.

    PubMed  CAS  Google Scholar 

  54. Yoshiji H, Kuriyama S, Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 2002;23(6):348–56. doi:10.1159/000069792.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by grants from the National Natural Science Foundation of China (Grant no. 30801370). The authors would like to thank the nurses in the Department of Urology in our hospital for their helpful work on sample collecting.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People’s Republic of China

    Xiao Wang, Shuai Wang, Yi-wei Lin, Jian Wu, Hong Chen, Ye-qing Mao, Xiang-yi Zheng, Cheng Zhou & Li-ping Xie

Authors
  1. Xiao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuai Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi-wei Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ye-qing Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiang-yi Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cheng Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Li-ping Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li-ping Xie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, X., Wang, S., Lin, Yw. et al. Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China. Med Oncol 29, 1964–1971 (2012). https://doi.org/10.1007/s12032-011-0051-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0051-5

Keywords

Search

Navigation